N. Vlatković

发表

Stimulation of human DNA polymerase e by MDM 2

Y. Li, D. Haines, S. Linn, 2022 .

p 53 Regulation and Function in Renal Cell Carcinoma

W. Linehan, M. Boyd, H. Warburton, 2005 .

p53 regulation and function in renal cell carcinoma.

W. Linehan, M. Boyd, H. Warburton, 2005, Cancer research.

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice

G. Dockray, A. Varró, R. Dimaline, 2012, Endocrinology.

Expression of human cationic trypsinogen (PRSS1) in murine acinar cells promotes pancreatitis and apoptotic cell death

Wei Huang, J. Neoptolemos, R. Mukherjee, 2014, Cell Death and Disease.

A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations

J. Slupsky, Anuradha Tarafdar, A. Michie, 2020, Scientific Reports.

MDM2 polymorphisms and cancer risk in basal cell carcinoma

M. Boyd, N. Vlatković, 2007, The British journal of dermatology.

Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.

M. Wilkie, M. Boyd, T. Jones, 2018, Oral oncology.

p53 and MDM2 in renal cell carcinoma

M. Boyd, M. Maguire, K. Parsons, 2010, Cancer.

Stimulation of human DNA polymerase ϵ by MDM2

Ying Li, Stuart Linn, D. Haines, 2003 .

The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer

Eithne Costello, R. Jackson, F. Campbell, 2013, International journal of cancer.

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy

R. Eccles, S. Coupland, H. Kalirai, 2012, BJU international.

p 53 and MDM 2 in Renal Cell Carcinoma Biomarkers for Disease Progression and Future Therapeutic Targets ?

M. Boyd, M. Maguire, K. Parsons, 2010 .

p53: a molecular marker for the detection of cancer.

M. Boyd, N. Vlatković, 2008, Expert opinion on medical diagnostics.

Regulation of p53 and MDM2 Activity by MTBP

M. Boyd, N. Vlatković, M. Brady, 2005, Molecular and Cellular Biology.

A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2*

D. Haines, M. Boyd, N. Vlatković, 2000, The Journal of Biological Chemistry.

Janus-faces of NME–oncoprotein interactions

M. Boyd, N. Vlatković, S. Chang, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Postnatal Changes in the Expression Pattern of the Imprinted Signalling Protein XLαs Underlie the Changing Phenotype of Deficient Mice

A. Plagge, N. Nunn, S. Krechowec, 2012, PloS one.

MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

B. K. Park, R. Jenkins, M. Boyd, 2008, Cancer research.

Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy

C. Rubbi, M. Boyd, N. Vlatković, 2013, Cellular and Molecular Life Sciences.

The nucleolus directly regulates p53 export and degradation

C. Rubbi, M. Boyd, Mark T. Boyd, 2011, The Journal of cell biology.

MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

S. Guerrera, Y. Li, D. Haines, 2000, Nucleic acids research.

TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies

C. Rubbi, M. Wilkie, M. Boyd, 2020, Cancer letters.

MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism

M. Boyd, H. Warburton, T. Devling, 2010, FEBS letters.

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.

J. Blaydes, C. Rubbi, A. Phillips, 2014, Cancer letters.

Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines

C. Rubbi, M. Wilkie, M. Boyd, 2021, Cancers.

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

C. Rubbi, R. Eccles, D. Sibson, 2010, British Journal of Cancer.

Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy

C. Rubbi, M. Boyd, N. Vlatković, 2014, Cellular and Molecular Life Sciences.

Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all.

C. Rubbi, M. Boyd, Kerryanne Crawford, 2011, Current pharmaceutical design.

Janus-faces of NME–oncoprotein interactions

M. Boyd, N. Vlatković, S. Chang, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Loss of MTBP expression is associated with reduced survival in a biomarker‐defined subset of patients with squamous cell carcinoma of the head and neck

T. Helliwell, C. Rubbi, M. Boyd, 2011, Cancer.

Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications

M. Wilkie, M. Boyd, T. Jones, 2015, The Lancet.

MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.

C. Rubbi, B. K. Park, R. Jenkins, 2011, Carcinogenesis.

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice

G. Dockray, A. Varró, R. Dimaline, 2012, Endocrinology.

The nucleolus directly regulates p53 export and degradation

C. Rubbi, M. Boyd, N. Vlatković, 2011, The Journal of cell biology.

Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy

R. Eccles, S. Coupland, H. Kalirai, 2012, BJU international.

Stimulation of human DNA polymerase epsilon by MDM2.

Ying Li, Stuart Linn, Y. Li, 2003, Nucleic acids research.